Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
McKesson
Cipla
Queensland Health
Chinese Patent Office
Farmers Insurance
Mallinckrodt
Medtronic
Citi
US Department of Justice

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,045,519

« Back to Dashboard

Summary for Patent: 9,045,519
Title:N-pyrazole A.sub.2A receptor agonists
Abstract: The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compound to stimulate mammalian coronary vasodilatation for imaging the heart. ##STR00001##
Inventor(s): Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata P. (Pune, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:14/020,736
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,045,519

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,045,519

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,403,567 N-pyrazole A2A adenosine receptor agonists ➤ Try a Free Trial
7,183,264 N-pyrazole A2A receptor agonists ➤ Try a Free Trial
7,655,637 N-pyrazole A.sub.2A receptor agonists ➤ Try a Free Trial
8,569,260 N-pyrazole A.sub.2A receptor agonists ➤ Try a Free Trial
8,278,435 N-pyrazole A2A receptor agonists ➤ Try a Free Trial
6,642,210 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists ➤ Try a Free Trial
7,144,872 N-pyrazole A.sub.2A receptor agonists ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,045,519

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I230161 ➤ Try a Free Trial
Turkey 200200588 ➤ Try a Free Trial
Portugal 1189916 ➤ Try a Free Trial
New Zealand 516334 ➤ Try a Free Trial
Norway 2011002 ➤ Try a Free Trial
Norway 322457 ➤ Try a Free Trial
Norway 20016350 ➤ Try a Free Trial
Mexico PA01013325 ➤ Try a Free Trial
Luxembourg 91785 ➤ Try a Free Trial
South Korea 100463300 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
McKesson
UBS
Chubb
Farmers Insurance
Julphar
Medtronic
Express Scripts
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot